For the period of 24 January 2022 to 30 January 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 24 January – 30 January 2022
Evidence brief for 17 January – 23 January 2022
For the period of 17 January 2022 to 23 January 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 17 January – 23 January 2022
Emtricitabine + Tenofovir Disoproxil Fumarate Fixed-Dose Combination as Oral Pre-Exposure Prophylaxis (PrEP) to Reduce the Risk of Sexually Acquired HIV-Infection
Date of publication: December 17, 2021 Decision of the Secretary of Health: Approved (18 January 2022) Evidence Summary: Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection Advisory for Appeals on Preliminary Recommendation: https://bit.ly/PrelimES-OralPrEP-Dec21 HTAC Recommendation Review:
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview: